Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Faron Pharmaceuticals Oy    FARN   FI4000153309

FARON PHARMACEUTICALS OY

(FARN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Faron Pharmaceuticals Oy : announces R&D Day to be held in June

share with twitter share with LinkedIn share with facebook
05/28/2020 | 02:01am EDT

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Company announcement, 28 May 2020 at 9.00 AM (EET)

 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT.

The event will provide an opportunity for the Company's management team to present its R&D strategy and provide insight into Faron's two clinical stage programmes. Management will discuss the Company's wholly-owned novel precision cancer immunotherapy, Clevegen, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. Management will also discuss Traumakine, for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), which is currently being investigated in COVID-19 patients in the ongoing REMAP-CAP trial and the WHO's Solidarity trial. There will be an opportunity to ask questions during the webcast.

For further information on the R&D Day, or to register for the event, please contact Consilium Strategic Communications at faron@consilium-comms.com or telephone +44 (0)20 3709 5700.

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Panmure Gordon (UK) Limited, Nomad and Broker

Emma Earl, Freddy Crossley (Corporate Finance)

James Stearns (Corporate Broking)

Phone: +44 207 886 2500

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen, Jussi Majamaa

Phone: +358 (0)40 555 4727

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com

https://news.cision.com/faron-pharmaceuticals-oy/r/faron-announces-r-d-day-to-be-held-in-june,c3121672

(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
Latest news on FARON PHARMACEUTICALS OY
06/17FARON PHARMACEUTICALS OY : Faron provides update on pipeline progress ahead of R..
AQ
06/17FARON PHARMACEUTICALS OY : Faron hosts virtual R&D Day today
AQ
06/16FARON PHARMACEUTICALS OY : Faron receives EUR2.1 million funding from Business F..
AQ
06/16FARON PHARMACEUTICALS OY : hosts virtual R&D Day today
AQ
06/16FARON PHARMACEUTICALS OY : update on pipeline progress ahead of R&D Day
AQ
06/15FARON PHARMACEUTICALS OY : receives EUR 2.1 million funding from BF
AQ
06/11FARON PHARMACEUTICALS OY : selected for EUR2.5 million grant from EIC
AQ
06/01FARON PHARMACEUTICALS OY : MATINS Update
AQ
05/29FARON PHARMACEUTICALS OY : Faron announces R&D Day to be held in June
AQ
05/28FARON PHARMACEUTICALS OY : announces R&D Day to be held in June
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -13,0 M -14,6 M -14,6 M
Net cash 2020 6,81 M 7,65 M 7,65 M
P/E ratio 2020 -9,55x
Yield 2020 -
Capitalization 145 M 181 M 163 M
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees 24
Free-Float 53,6%
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 5,34 €
Last Close Price 3,15 €
Spread / Highest target 69,6%
Spread / Average Target 69,6%
Spread / Lowest Target 69,6%
EPS Revisions
Managers
NameTitle
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Frank Murdoch Armstrong Non-Executive Chairman
Toni Haenninen Chief Financial Officer
Matti Karvonen Chief Medical Officer & VP-Drug Development
Matti Esa Manner Non-Executive Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
FARON PHARMACEUTICALS OY27.62%195
GILEAD SCIENCES, INC.17.05%95 408
VERTEX PHARMACEUTICALS30.75%74 226
REGENERON PHARMACEUTICALS62.24%61 863
WUXI APPTEC CO., LTD.41.34%30 875
GENMAB A/S47.28%21 551